(Q44369824)

2 December 2017

title

Increased phospholipase A2 activity in schizophrenia with absent response to niacin (English)

1 reference

2 December 2017

0 references

5

Wagner F Gattaz

1 reference

2 December 2017

Hildeberto Tavares

1

1 reference

2 December 2017

Juliana Yacubian

series ordinal

2

1 reference

2 December 2017

Leda L Talib

series ordinal

3

1 reference

2 December 2017

Nádia R Barbosa

series ordinal

4

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

2 December 2017

published in

Schizophrenia Research

1 reference

2 December 2017

volume

61

1 reference

2 December 2017

issue

1

1 reference

2 December 2017

page(s)

1-6

1 reference

Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Increased platelet phospholipase A2 activity in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Membrane fatty acids, niacin flushing and clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Haloperidol downregulates phospholipase A(2) signaling in rat basal ganglia circuits

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Niacin test in schizophrenia and affective illness

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Effects of antipsychotic treatment on membrane phospholipid metabolism in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Effect of neuroleptics on phospholipase A2 activity in the brain of rats

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

Niacin skin flush in schizophrenia: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2802%2900281-5

7 January 2021

10.1016/S0920-9964(02)00281-5

Identifiers

DOI

1 reference

2 December 2017

1 reference